healthcare organization

South London and Maudsley NHS Foundation Trust

GB

OPENALEX: I200323923 ROR: 015803449

People

Connected researchers

Public evidence

57 connected articles

Cannabis-Based Medicinal Products for Endometriosis: A 2-Year Prospective Analysis From the UK Medical Cannabis Registry.2026 · PubMed Central Open Access UK Medical Cannabis Registry: an updated analysis of clinical outcomes of medicinal cannabis therapy for hypermobility-associated chronic pain2026 · PubMed Central Open Access UK Medical Cannabis Registry: a case series analysing clinical outcomes of medicinal cannabis therapy for fibromyalgia.2026 · Europe PMC Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.2026 · Europe PMC A Longitudinal Assessment of Endometriosis Patients Prescribed Cannabis-Based Medicinal Products: A Case Series From the UK Medical Cannabis Registry.2026 · Europe PMC UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Epilepsy.2025 · Europe PMC Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMC The impact of childhood trauma and cannabis use on paranoia: a structural equation model approach.2025 · Europe PMC Applying machine learning to international drug monitoring: classifying cannabis resin collected in Europe using cannabinoid concentrations.2025 · Europe PMC Are reasons for first using cannabis associated with subsequent cannabis consumption (standard THC units) and psychopathology?2025 · Europe PMC

Registered research

Connected studies

Body Project SMIL: Effectiveness of Virtually Delivered Body Project Groups to Prevent Eating Disorders Among Young Women With Psychiatric Illnessnct06893627 Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393 Effects of Cannabidiol (CBD) on the Brainnct04831294 Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosisnct07245212

Matched by exact identifiers only. Profile data: OpenAlex.

Mood instability as a transdiagnostic predictor of cannabis use in attention-deficit/hyperactivity disorder and depression: A natural language processing analysis of electronic health records from 13,025 adolescents.

2025 · Europe PMC

UK medical cannabis registry: A clinical outcome analysis of medical cannabis therapy in chronic pain patients with and without co-morbid sleep impairment.2025 · Europe PMC

UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility-Associated Chronic Pain.2025 · Europe PMC

The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMC

A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.2024 · Europe PMC

What impact could the legalisation of recreational cannabis have on the health of the UK? Lessons from the rest of the world.2024 · Europe PMC

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.2024 · Europe PMC

A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disorders.2024 · Europe PMC

UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia.2024 · Europe PMC

The Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMC

Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry.2023 · PubMed Central Open Access

Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy-Analysis from the UK Medical Cannabis Registry.2023 · PubMed Central Open Access

Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users2023 · PubMed Central Open Access

Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry.2023 · PubMed Central Open Access

First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open Access

The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMC

Cannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.2023 · Europe PMC

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMC

Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies.2023 · PubMed Central Open Access

Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry.2022 · PubMed Central Open Access